Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.79 |
| ▸ | PDE1A | P54750 | 5/20 | 0.79 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.79 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PDE6C | P51160 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174349 | 0.88 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL1202 | 0.88 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6339988 | 0.88 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL5459779 | 0.88 | PDE5A (0.64) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6340027 | 0.85 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6332949 | 0.84 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6330040 | 0.84 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6340254 | 0.84 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6334065 | 0.84 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6340296 | 0.84 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | THE INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1695976-A1 | PYRAZOLOPYRIMIDINETHIONE DERIVATIVES, SALTS AND SOLVATES THEREOF, PREPARATION METHODS AND USE THEREOF | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-08-30 | — | — | EP | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE1A 33/4885PDE1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.